Abstract
To test whether genetic variation in the CYP system may influence the statin response, a promoter (A-290G) and 2 nonsynonymous polymorphisms (F189S and M445T) in the CYP3A4 gene locus were examined in 340 hypercholesterolemic patients who were treated with atorvastatin 10 mg. The A-290G variant allele was significantly associated with higher levels of post-treatment low-density lipoprotein cholesterol, whereas the M445T variant was associated with lower levels of low-density lipoprotein cholesterol before and after treatment.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Anticholesteremic Agents / therapeutic use
-
Atorvastatin
-
Cholesterol / blood
-
Cholesterol, HDL / blood
-
Cholesterol, LDL / blood
-
Cytochrome P-450 CYP3A
-
Cytochrome P-450 Enzyme System / genetics*
-
Female
-
Genetic Variation
-
Genotype
-
Heptanoic Acids / therapeutic use
-
Humans
-
Hypercholesterolemia / blood*
-
Hypercholesterolemia / drug therapy
-
Hypercholesterolemia / genetics*
-
Lipoproteins / blood*
-
Male
-
Middle Aged
-
Pyrroles / therapeutic use
-
Triglycerides / blood
Substances
-
Anticholesteremic Agents
-
Cholesterol, HDL
-
Cholesterol, LDL
-
Heptanoic Acids
-
Lipoproteins
-
Pyrroles
-
Triglycerides
-
Cytochrome P-450 Enzyme System
-
Cholesterol
-
Atorvastatin
-
CYP3A protein, human
-
Cytochrome P-450 CYP3A
-
CYP3A4 protein, human